A Canadian based oncology biotechnology company is developing targeted treatments for patients who need them the most.

The leading compound SP-2577 represents a potential paradigm shift in the treatment of cancer. They are initially targeting Ewing sarcoma, a devastating pediatric, adolescent and young adult bone cancer where there are no targeted therapies currently available. Moreover, the discovery may also apply to other cancers such as prostate, breast, ovarian, and other conditions like leukemia.

This company is the recipient of a 3-year $18.7 million Cancer Prevention and Research Institute of Texas (CPRIT) New Company Product Development award, and receives support from organizations like the National Pediatric Cancer Foundation.